Navigation Links
ATS publishes clinical practice guidelines on sleep apnea and driving
Date:5/31/2013

The American Thoracic Society has released new clinical practice guidelines on sleep apnea, sleepiness, and driving risk on non-commercial drivers.

The new guidelines, which are an update of a 1994 ATS statement on this topic, appear in the June 1, 2013 American Journal of Respiratory and Critical Care Medicine.

"Up to 20 percent of crashes that occur on monotonous roads can be attributed to sleepiness, and the most common medical cause of excessive daytime sleepiness is obstructive sleep apnea (OSA)," said Kingman P. Strohl, MD, program director, sleep medicine, University Hospitals Case Medical Center, director of the Center for Sleep Disorders Research at Case Western Reserve University and chair of the committee that drafted the guidelines. "With these new guidelines, we aimed to provide healthcare practitioners with a framework for the assessment and management of sleepy driving in the evaluation of OSA."

The guidelines' recommendations include the following:

  • All patients undergoing initial evaluation for suspected or confirmed OSA should be asked about daytime sleepiness and recent unintended motor vehicle crashes or near-misses attributable to sleepiness, fatigue, or inattention. Patients with these characteristics are considered high-risk drivers and should be warned about the potential risk of driving until effective therapy is initiated.

  • Additional information that should be elicited during initial evaluation for suspected or confirmed OSA includes the clinical severity of the OSA and treatment that the patient has received, including behavioral interventions. Adherence and response to therapy should be assessed at subsequent visits. Drowsy driving risk should be reassessed at subsequent visits if it was initially increased.

  • For patients in whom there is a high clinical suspicion of OSA and who have been deemed high-risk drivers:

    • Polysomnography should be performed and, if indicated, treatment initiated as soon as possible, rather than delayed until convenient. For patients with no comorbidities and a high clinical suspicion for OSA, at-home portable monitoring is a reasonable alternative to polysomnography.
    • Empiric continuous positive airway (CPAP) should not be used for the sole purpose of reducing driving risk.

  • For patients with confirmed OSA who have been deemed high-risk drivers, CPAP therapy to reduce driving risk is recommended, rather than no treatment.

  • For patients with suspected or confirmed OSA who have been deemed high-risk drivers, stimulant medications for the sole purpose of reducing driving risk are not recommended.

  • Opportunities to improve clinical practice include the following:

    • Clinicians should develop a practice-based plan to inform patients and their families about drowsy driving and other risks of excessive sleepiness, as well as behavioral methods that may reduce those risks.
    • Clinicians should routinely inquire in patients suspected with OSA about non-OSA causes of excessive daytime sleepiness, co-morbid neurocognitive impairments, and diminished physical skills, which may additively contribute to crash risk and affect the efficacy of sleep apnea treatment.
    • Clinicians should familiarize themselves with local and state statutes or regulations regarding the compulsory reporting of high-risk drivers with OSA.

"Addressing the issue of drowsy driving requires the combined effort of physicians, patients, and policy makers," said Dr. Strohl. "The assessment for sleepiness before and with treatment of OSA, as outlined in these new guidelines, is an essential part of these joint efforts."


'/>"/>

Contact: George Stamatis
george.stamatis@uhhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
2. Moffitt researcher publishes book on nutritional management of cancer treatment effects
3. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
4. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
5. ASTRO publishes Safety is No Accident: A Framework for Quality Radiation Oncology and Care
6. Annals of Internal Medicine publishes new CDC recommendations on hepatitis C screening
7. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
8. Using an HRA to Comply with San Francisco's HCSO Requirements - Zane Benefits Publishes Information
9. Zane Benefits Publishes Information About Over-the-Counter (OTC) Medicines, Drugs and HRAs
10. Defined Contribution: A Healthcare Win for Brokers, Employers & Employees - Zane Benefits Publishes Information
11. ISA Surgical Publishes Real Stories of the Benefits of Medical Tourism In Mexico From US And Canadian Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Switzerland (PRWEB) , ... April 24, 2017 , ... ... steps to become familiar. This makes it difficult for lab operators and management ... systematic methodology to help them identify wasteful or unnecessary actions. , Created ...
(Date:4/24/2017)... ... 2017 , ... “Reflections of God’s Work”: an enlightening collection of life lessons ... creation of published author, Jerri Broglin, a survivor of great loss who gained insight ... great eye-opener for those searching for answers, as we are finding the answers that ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue ... Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), ... ANCD BRAIN device as the product advances towards regulatory and clinical phases. , ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication Solutions, a ... Cisco Select certification and SMB specialization. Altura is now qualified to sell, ... earning the Select Certification, Altura fulfilled the training and exam requirements for the ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: